Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 405-490-3 | CAS number: 613-62-7 BENZYL-2-NAPHTHYLETHER; BETA-NAPHTHYLBENZYLETHER (BON); BNE; BON; NIPAFAX BNE; SENSLON-50; ZO-1
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 30 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 30 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
- Modified dose descriptor starting point:
- NOAEC
Local effects
Acute/short term exposure
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.3 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 4.3 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 100
- Modified dose descriptor starting point:
- NOAEL
Workers - Hazard for the eyes
Additional information - workers
1. Identification of relevant dose descriptor
For the derivation of the DNELs, the 90-Day oral toxicity study in rats was qualified as the most relevant study. The dose descriptor chosen was the NOAEL of 427 mg/kg/day.
2. Mode of action
No non-threshold mode of action is associated with the test substance. In particular, the test substance has no genotoxic potential.
3. Correction of dose descriptor
NOAEL (oral) is converted into a NOAEL(corrected)in accordance toGuidance on information requirements and chemical safety assessment, Chapter R.8: Characterization of dose[concentration]-response for human health, ECHA, May 2008.
Workers: NOAEL (oral) = 427 mg/kg bw =>NOAEL(corrected)= 753 mg/m3
4. Application of assessment factors
The following assessment factors were chosen: A correction for differences in metabolic rate per body weight was made by an allometric scaling factor of 4 (except for inhalation), remaining differences account for 2.5. Intraspecies differences account for a factor of 5. For exposure duration a factor of 2 is employed. Overall, assessment factors of 100 and 25 were employed for oral/dermal and inhalation route, respectively.
5.Selection of the critical DNEL(s)/DMELs and/or qualitative/semi-quantitative descriptor for critical health effects
DNEL- acute, inhalation, systemic:The acute DNELs could not be calculated directly but the long-term DNELs are sufficient to ensure that acute effects do not occur, provided high-peak acute exposure (especially for inhalation) can be avoided.
DNEL- acute, inhalation, local:
Not quantifiable.
DNEL- acute, dermal, systemic: The acute DNELs could not be calculated directly but the long-term DNELs are sufficient to ensure that acute effects do not occur, provided high-peak acute exposure can be avoided.
DNEL- acute, dermal, local:
Not quantifiable
DNEL- long-term, inhalation, local:
Not quantifiable.
DNEL- long-term, inhalation, systemic:
NOAEL (corrected) / Sum of assessment factors applicable
753 mg/m3 /25 = 30 mg/m3
DNEL- long-term, dermal, systemic:
NOAEL (oral) / Sum of assessment factors applicable
427 mg/kg bw / 100 = 4.3 mg/kg bw
The
dermal route is typically covered by oral route information in the
absence of data for this administration route.
DNEL- long-term, dermal, local:
Not quantifiable and not considered applicable.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7.4 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 7.4 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 50
- Modified dose descriptor starting point:
- NOAEC
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.1 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 200
- Modified dose descriptor starting point:
- NOAEL
General Population - Hazard for the eyes
Additional information - General Population
1. Identification of relevant dose descriptor
For the derivation of the DNELs, the 90-Day oral toxicity study in rats was qualified as the most relevant study. The dose descriptor chosen was the NOAEL of 427 mg/kg/day.
2. Mode of action
No non-threshold mode of action is associated with the test substance. In particular, the test substance has no genotoxic potential.
3. Correction of dose descriptor
NOAEL (oral) is converted into a NOAEL(corrected)in accordance toGuidance on information requirements and chemical safety assessment, Chapter R.8: Characterization of dose[concentration]-response for human health, ECHA, May 2008.
General population: NOAEL (oral) = 427 mg/kg bw =>NOAEL(corrected)= 371 mg/m3
4. Application of assessment factors
The following assessment factors were chosen: A correction for differences in metabolic rate per body weight was made by an allometric scaling factor of 4 (except for inhalation), remaining differences account for 2.5. Intraspecies differences account for a factor of 5. For exposure duration a factor of 2 is employed. Overall, assessment factors of 200 and 50 were employed for oral/dermal and inhalation route, respectively.
5.Selection of the critical DNEL(s)/DMELs and/or qualitative/semi-quantitative descriptor for critical health effects
DNEL- acute, inhalation, systemic:The acute DNELs could not be calculated directly but the long-term DNELs are sufficient to ensure that acute effects do not occur, provided high-peak acute exposure (especially for inhalation) can be avoided.
DNEL- acute, inhalation, local:
Not quantifiable.
DNEL- acute, dermal, systemic: The acute DNELs could not be calculated directly but the long-term DNELs are sufficient to ensure that acute effects do not occur, provided high-peak acute exposure can be avoided.
DNEL- acute, dermal, local:
Not quantifiable
DNEL- long-term, inhalation, local:
Not quantifiable.
DNEL- long-term, inhalation, systemic:
NOAEL (corrected) / Sum of assessment factors applicable
371 mg/m3 /50 = 7.4 mg/m3
DNEL- long-term, dermal, systemic:
NOAEL (oral) / Sum of assessment factors applicable
427 mg/kg bw / 200 = 2.1 mg/kg bw
The
dermal route is typically covered by oral route information in the
absence of data for this administration route.
DNEL- long-term, dermal, local:
Not quantifiable and not considered applicable.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
